Clinical Trial Update: Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing trastuzumab deruxtecan to standard chemotherapy in HER2-expressing endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Endometrial Cancer | Phase 3 | Status: RECRUITING